Logo
X

X4 Pharmaceuticals

134 employees

We are a fully integrated, commercial-stage biopharmaceutical company driving progress for people living with rare immune disorders. We listen to people whose challenges have been long overlooked, understand their needs, and develop solutions to their most urgent and critical health concerns. Our FDA-approved medication XOLREMDI® (mavorixafor) is commercially available in the U.S. in its first indication. We are evaluating mavorixafor in additional potential indications, and have an ongoing global, pivotal Phase 3 clinical trial for its use in chronic neutropenia. Our corporate headquarters is in Boston, Massachusetts.

Investor insights

Funding rounds participated in

$115M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2014

Funding rounds raised

Total raised

$115M

from 1 investors over 1 rounds

X

X4 Pharmaceuticals raised $115M on September 3, 2023

Investors: Hercules Capital

FAQ